Neurocrine Biosciences Inc.
12780 El Camino Real
San Diego,
CA 92130
United States - Map
Phone: 858-617-7600
Fax: 858-617-7601
Web Site: http://www.neurocrine.com
| Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The companys research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Kevin C. Gorman Ph.D., 51
Chief Exec. Officer, Pres |
$
680.00K |
$
0 | Dr. Wylie W. Vale Ph.D., 67
Co-Founder, Board Member and Member of Compensation Committee |
N/A
| N/A | Mr. Timothy P. Coughlin , 42
Chief Financial Officer, Principal Accounting Officer and VP |
$
437.00K |
$
0 | Dr. Margaret E. Valeur-Jensen J.D., Ph.D., 52
Exec. VP, Corp. Sec. and Gen. Counsel |
$
585.00K |
$
0 | Dr. Christopher F. OBrien M.D., 52
Chief Medical Officer and Sr. VP |
$
515.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
